NCT01517698View on ClinicalTrials.gov

A Study of RO4917523 in Patients With Fragile X Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

185

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
Fragile X Syndrome
Interventions
DRUG

Placebo

placebo to RO4917523 orally once a day for 12 weeks

DRUG

RO4917523 0.5 mg

0.5 mg orally once a day for 12 weeks

DRUG

RO4917523 1.5 mg

1.5 mg orally once a day for 12 weeks

Trial Locations (51)

1425

Caba

8000

Bahía Blanca

10029

New York

10314

Staten Island

13385

Marseille

19063

Media

20009

Donostia / San Sebastian

20010

Washington D.C.

20030

Aguascalientes

21079

Dijon

21205

Baltimore

27710

Durham

28040

Madrid

28046

Madrid

29620

Torremolinos

30033

Decatur

30120

El Palmar. Murcia

33076

Bordeaux

34295

Montpellier

37044

Tours

37203

Nashville

40202

Louisville

45229

Cincinnati

60612

Chicago

69003

Bron

75013

Paris

77030

Houston

78258

San Antonio

80045

Aurora

85006

Phoenix

90806

Long Beach

95817

Sacramento

98145

Seattle

2340000

Valparaíso

52242-1083

Iowa City

01655

Worcester

C1126AAB

Caba

L6Y 1M5

Brampton

J1H 5N4

Sherbrooke

Unknown

Santiago

Lima

04530

México

Lima 33

Lima

08195

San Cugat Del Valles

411 19

Gothenburg

BT12 6AB

Belfast

DD1 9SY

Dundee

EH10 5HF

Edinburgh

GS 8SJ

Glasgow

W1W 7EJ

London

M13 9WL

Manchester

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT01517698 - A Study of RO4917523 in Patients With Fragile X Syndrome | Biotech Hunter | Biotech Hunter